Plain-English translation of NCT06563388 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether treating cancer that has spread to other parts of your body with a special type of radiation called SABR (stereotactic ablative radiotherapy) works best when given immediately alongside standard chemotherapy, or whether waiting three months before adding the radiation is just as effective. The study involves patients with lung, colorectal, or prostate cancer that has spread to 1–10 different locations in the body.
When cancer spreads to a few distant sites, doctors aren't sure whether attacking those spots with radiation right away helps patients live longer, or whether the standard chemotherapy alone works just as well. This trial will help answer that important question.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one group will receive standard chemotherapy followed by radiation therapy to treat the cancer spread, while the other group will receive radiation therapy immediately along with the standard chemotherapy. You will need to complete imaging and restaging within 12 weeks before starting treatment. Throughout the trial, you'll have regular visits with your cancer care team to monitor how you're doing and track your response to treatment.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States